MaxCyte Agrees to Acquire Akron Bio

MaxCyte signed a definitive agreement on November 9, disclosed November 10, to buy cell-therapy reagent supplier Akron Bio for stated total consideration of $151.8 million and secured a credit facility of up to $75…





